Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for breast cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative BreastCancer. Unresectable locally advanced or metastatic triple-negative (hormone-receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) breastcancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)-paclitaxel may enhance the anticancer activity of atezolizumab.In this phase 3 trial, we randomly assigned (in a 1:1 ratio) patients with untreated metastatic triple-negative breast (...) tumors, the median overall survival was 25.0 months and 15.5 months, respectively (hazard ratio, 0.62; 95% CI, 0.45 to 0.86). No new adverse effects were identified. Adverse events that led to the discontinuation of any agent occurred in 15.9% of the patients who received atezolizumab plus nab-paclitaxel and in 8.2% of those who received placebo plus nab-paclitaxel.Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breastcancer in both
signaling are associated with a more aggressive tumor phenotype. Validation of these associations in tissues from randomized trials may support targeted therapy to reduce breastcancer recurrence. (...) Molecular determinants of post-mastectomy breastcancer recurrence Breastcancer (BC) adjuvant therapy after mastectomy in the setting of 1-3 positive lymph nodes has been controversial. This retrospective Translational BreastCancer Research Consortium study evaluated molecular aberrations in primary cancers associated with locoregional recurrence (LRR) or distant metastasis (DM) compared to non-recurrent controls. We identified 115 HER2 negative, therapy naïve, T 1-3 and N 0-1 BC patients
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breastcancer survivors: systematic review. To investigate the effect of endocrine therapies on a wide range of specific clinical cardiovascular disease outcomes in women with a history of non-metastatic breast cancer.Systematic review and meta-analysis of randomised controlled trials and observational studies.Medline and Embase up until June 2018.Studies were included if they investigated the risk of a specific (...) thromboembolism and myocardial infarction, progressing knowledge. Although the choice of aromatase inhibitor or tamoxifen will primarily be based on the effectiveness against the recurrence of breastcancer, this review shows that the individual patient's risk of venous or arterial vascular disease should be an important secondary consideration.Prospero CRD42017065944.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http
Axillary Lymph Node Dissection for BreastCancer: Efficacy and Complication in Developing Countries Axillary lymph node dissection (ALND) frequently is performed as part of the surgical management of breastcancer as a therapeutic and prognostic index, but increasingly has been perceived as associated with significant complications. Data on efficacy and complications of ALND in Sudan are lacking. The aim of this study was to assess the efficacy and complications of ALND in patients with breast (...) cancer treated with mastectomy and breast-conserving surgery.We performed a prospective, hospital-based study in women with invasive breastcancer who underwent modified radical mastectomy or breast-conserving surgery with ALND between September 2014 and August 2015. The efficacy of ALND was defined as retrieval of ≥ 10 lymph nodes. Complications of ALND were assessed objectively and subjectively and defined as either present or absent.Of 96 patients with breastcancer included in the study, 40 (42
for breastcancer. In addition, for women with dense breasts, small tumors may be missed on mammography and the sensitivity of screening is diminished. At the time of publication, 35 states had passed laws mandating that breast density be reported in the letters that radiologists send to women with their mammogram results. The mandated language may be challenging for patients to understand, and such reporting may increase worry for women who are told that their risk for breastcancer is higher than (...) Should This Woman With Dense Breasts Receive Supplemental BreastCancer Screening?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Breastcancer will develop in 12% of women during their lifetime and is the second leading cause of cancer death among U.S. women. Mammography is the most commonly used tool to screen for breastcancer. Considerable uncertainty exists regarding the age at which to begin screening and the optimal screening interval. Breast density is a risk factor
included “blood pressure” and “lymphedema” and (“breastcancer” or “breastneoplasm”). The quality of evidence was assessed using the GRADE Working Group guidelines. Results: A total of 4 articles were included in this systematic review, all of which were prospective cohort studies. Three studies found no significantly increased risk of lymphedema with blood pressure measurements. One study measured lymphedema using 3 different techniques and found a significantly increased risk with one (...) of the techniques but not the others. Conclusion: This systematic review refutes the current guidelines that patients should avoid blood pressure monitoring in the affected arm. Further research that looks at how to define lymphedema and how to best diagnose it in the clinic will help with implementing earlier treatment. Keywords: Blood pressure, lymphedema, breastcancer, and breastneoplasm Recommended Citation Braesch, Chelsea, "Blood Pressure Measurement as a Risk Factor for Lymphedema in Females Post
Manual lymph drainage may not have a preventive effect on the development of breastcancer-related lymphoedema in the long term: a randomised trial What are the short-term and long-term preventive effects of manual lymph drainage (MLD), when used in addition to information and exercise therapy, on the development of lymphoedema after axillary dissection for breastcancer?Randomised controlled trial with concealed allocation, blinded assessors and intention-to-treat analysis.Adults undergoing (...) unilateral dissection for breastcancer were recruited, with 79 allocated to the experimental group and 81 to the control group.The experimental group received guidelines about prevention of lymphoedema, exercise therapy and MLD. The control group received the same guidelines and exercise therapy, but no MLD. The interventions in both groups were delivered for 6 months.The primary outcome was cumulative incidence of arm lymphoedema defined in four ways (≥200ml,≥2cm,≥5%, and≥10% increase), which represent
The Effect on Quality of Life and Body Image of Mastectomy Among BreastCancer Survivors The objective of the present study was to determine effect on quality of life (QoL) and body image level following mastectomy among breastcancer (BC) survivors.In this descriptive study was carried out between February 2015 and December 2016 with 57 women with modified radical mastectomy and who in stage II and stage III. Data were collected using the socio-demographic and body cathexis scale, Functional (...) Assessment of Cancer Therapy-Breast (FACT-B) to determine QoL. The study was carried out in home environment in which women lived.The average age of the women was 49.34 years (ranged 28-78 years). Most of the women had undergone mastectomy for more than 6 months.. Most of the women also received adjuvant chemotherapy and radiotherapy. The study showed that the mean FACT-B total score of the women was 68.47 (SD=22.44), and the body image score was 121.61(SD=21.96). According to the results of linear
%) were triple negative (TNBC) by immunohistochemistry. There were no statistically significant differences between subtypes in terms of histological type, grade, tumour size and lymph node status. Median disease-free survival was 47 months (95% confidence interval [CI] 29.2-82.6) and median overall survival was 75 months (95% CI 64.7-90.8). Triple negative breastcancer showed poorer outcome than other subgroups. Presence of TNBC disease was associated with poorer outcome compared to luminal A (HR (...) between March 2000 and December 2015 were retrospectively reviewed. Patient demographics, clinical and pathological feature of the primary tumour, adjuvant treatment options and survival data were analysed. Intrinsic breastcancer subtypes were defined according to ER, PR, HER-2 and ki-67 status.We identified 129 non-metastatic inflammatory breastcancer patients. Median follow-up was 73 months. 10 (7.7%) were luminal A-like, 67 (51.9%) were luminal B-like, 37 (28.6%) were HER-2 positive, and 15 (11.6
QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early BreastCancer A previous randomized phase II study showed that neoadjuvant nab-paclitaxel (nab-PTX) 100 mg/m2) was effective and well-tolerated in patients with HER2-negative early-stage breastcancer, compared with docetaxel (DTX). We evaluated patient outcomes in terms of the Functional Assessment of Cancer Therapy-Breast (FACT-B), as a measure of health-related quality of life (HRQoL).Stage I-III HER2-negative breastcancer patients
Impact of The Method of Diagnosis on The Stage of BreastCarcinoma Screening mammography is recommended to women at a certain age to achieve an early diagnosis. The purpose of this study is to find out how breastcarcinoma was diagnosed and the impact of the method of diagnosis on the stage of the tumor.In this study, 903 operated breastcancer patients, between 2010-2016, in a large volume Marmara University Istanbul Pendik Education and Research Hospital were analyzed retrospectively (...) patients (65.7%) were diagnosed with a mass in the breast, while 241 (32.6%) patients were diagnosed with screening with mammography. Twelve patients (1.7%) presented with nipple discharge. Median tumor sizes measured in the resected specimen were 22 mm, 21 mm, and 21 mm in patients diagnosed with a mass, screening, and nipple discharge respectively. The difference among the groups were not significant (p=0.460).Axillary lymph nodes were positive in 210 (43.3%) of patients presenting with a mass
Risk-Reducing Options for Women with a Hereditary BreastCancer Predisposition Genetic testing is now widely utilized to identify women with a hereditary predisposition for breastcancer. Women who carry mutations that increase breastcancer risk may consider three options to reduce risk: screening, chemoprevention, and prophylactic surgery. Yet, no randomized trials have specifically assessed the efficacy of these options in mutation carriers. In many developed countries, mammography (...) is regarded as the optimal means of screening for breastcancer in the general population. However, breast MRI is a more sensitive screening tool, and for mutation carriers, any breastcancer screening strategy should incorporate screening with MRI. In randomized trials of women at high risk for developing breastcancer, chemoprevention reduces that risk, but it has not been shown to reduce mortality. Finally, observational studies suggest that, in mutation carriers, prophylactic surgery may reduce
The Significance of Extent of Extracapsular Extension in Patients with T1-2 and N1 BreastCancer The prognostic importance of extracapsular extension (ECE) in breastcancer is not yet clear, especially in patients with pathological T1-2 and N1 (pT1-2N1) disease. We aimed to investigate whether the extent of ECE was an independent prognostic factor for survival outcomes in patients with pT1-2N1 breast cancer.A total number of 131 patients with pT1-2N1 breastcancer treated between 2009 and 2015 (...) in pT1-2N1 breastcancer patients and grade 3-4 ECE seems to be notably associated with a shorter OS and DFS.
Evaluation of BreastCancer (BC) Awareness among Female University Students in Zarqa University, Jordan The purposes of this study were to assess the level of BreastCancer (BC) awareness of Jordanian female university students, measure their attitudes toward BC treatment, and compare the level of awareness and attitudes of students in the science and humanities faculties.The current study was cross-sectional and conducted among female students in Zarqa University in Jordan. Stratified random
Androgen receptor expression in normal breast tissue and subsequent breastcancer risk Sex steroid hormone signaling is critical in the development of breastcancers, although the role of the androgen receptor remains unclear. This study evaluated androgen receptor (AR) expression in normal breast tissue as a potential marker of breastcancer risk. We conducted a nested case-control study of women with benign breastdisease (BBD) within the Nurses' Health Studies. Epithelial AR expression (...) was assessed by immunohistochemistry in normal tissue from the BBD biopsy and the percent of positive nuclei was estimated in ordinal categories of 10% for 78 breastcancer cases and 276 controls. Logistic regression models adjusting for the matching factors and BBD lesion type were used to calculate odds ratios (ORs) for the association between AR expression (tertiles: ≤10%, 11-30%, and >30%) and breastcancer risk. AR expression in normal breast tissue was not associated with subsequent breastcancer
trastuzumab treatment, to determine accurate prognosis. We propose a retrospective multicenter cohort study in China to validate CPS + EG, Neo-Bioscore, and the modified Neo-Bioscore system and determine the accuracy of prediction. Primary breastcancer patients without metastasis treated with PST and surgery in academic institutions or hospitals of provincial level in China will be included. Disease-free, disease specific, and overall survival will be calculated using the Kaplan-Meier Method, stratified (...) Validation of CPS+EG, Neoâ€Bioscore, and modified Neoâ€Bioscore staging systems after preoperative systemic therapy of breastcancer: Protocol of a retrospective multicenter cohort study in China Prognostic assessment after preoperative systemic therapy (PST) is critical to develop a therapeutic strategy for breastcancer management. Currently, a clinical-pathologic staging system that incorporates ER status and nuclear grading (CPS + EG), and the Neo-Bioscore system that includes HER2 status
Survival estimates stratified by the Nottingham Prognostic Index for early breastcancer: a systematic review and meta-analysis of observational studies. Estimates of survival for women diagnosed with early staged breastcancer are available based on stratification into prognostic categories defined using the Nottingham Prognostic Index (NPI). This review aimed to identify and summarize the estimated survival statistics from separate sources in the literature and to explore the extent (...) of between-study heterogeneity in survival estimates.Observational studies in women diagnosed with early and locally advanced breastcancer reporting overall survival by NPI category were identified using a systematic literature search. An exploratory meta-analysis was conducted to describe survival estimates and assess between-study heterogeneity.Twenty-eight studies were identified. Nineteen studies with sufficient data on overall survival were included in meta-analysis. A high level of heterogeneity
Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With BreastCancer Purpose Over the past three decades, the incidence rate of breastcancer (BC) among Arab women has continually increased. However, data on the prevalence of BRCA1/2 mutations are scarce. Although the population in Saudi Arabia is at large homogeneous and consanguinity is common, especially in the central, eastern, and southern regions of the country, the prevalence of BRCA1 and BRCA2 mutations
Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breastcancer Detection of disseminated tumor cells (DTCs) in bone marrow is an established negative prognostic factor. We isolated small pools of (~20) EPCAM-positive DTCs from early breastcancer patients for genomic profiling. Genome-wide copy number profiles of DTC pools (n = 45) appeared less aberrant than the corresponding primary tumors (PT, n = 16). PIK3CA mutations were (...) ). We observed high discordance between ESR1 (40%) and ERRB2 (43%) expression in DTC pools vs. the clinical ER and HER2 status of the corresponding primary tumors, suggesting plasticity of biomarker status during dissemination to the bone marrow. Comparison of expression profiles of DTC pools with available data from circulating tumor cells (CTCs) of metastatic breastcancer patients revealed gene expression signatures in DTCs that were unique from those of CTCs. For example, ALDH1A1, CAV1, and VIM
Correlating nuclear morphometric patterns with estrogen receptor status in breastcancer pathologic specimens In this pilot study, we introduce a machine learning framework to identify relationships between cancer tissue morphology and hormone receptor pathway activation in breastcancer pathology hematoxylin and eosin (H&E)-stained samples. As a proof-of-concept, we focus on predicting clinical estrogen receptor (ER) status-defined as greater than one percent of cells positive for estrogen (...) receptor by immunohistochemistry staining-from spatial arrangement of nuclear features. Our learning pipeline segments nuclei from H&E images, extracts their position, shape and orientation descriptors, and then passes them to a deep neural network to predict ER status. After training on 57 tissue cores of invasive ductal carcinoma (IDC), our pipeline predicted ER status in an independent test set of patient samples (AUC ROC = 0.72, 95%CI = 0.55-0.89, n = 56). This proof of concept shows that machine